Jun 7 |
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
|
Jun 6 |
Gilead Says Bulevirtide With PegIFN Data 'Superior' to Bulevirtide Monotherapy; Achieves 46% Rate of Undetectable HDV RNA
|
Jun 6 |
Gilead’s seladelpar shows promise in primary biliary cholangitis trial
|
Jun 6 |
Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA
|
Jun 5 |
Gilead Sciences, Inc. (GILD) Jefferies 2024 Global Healthcare Conference
|
Jun 5 |
Should You Buy the 3 Highest-Yielding Dividend Stocks in the Nasdaq-100?
|
Jun 5 |
Gilead Sciences: Preserving Fertility in the Face of a Cancer Diagnosis
|
Jun 5 |
Lilly details MASH data for tirzepatide; Cytokinetics comments on past sale talks
|
Jun 5 |
The Dividend Dynamos: 7 Stocks That Will Energize Your Income Stream
|
Jun 5 |
7 Dividend Stocks to Invest In for a Lifetime of Income
|